Targeting Rb mutant cancers by inactivating TSC2

Jennifer S. Searle; Binghui Li; Wei Du

doi:10.18632/oncotarget.130

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Perspectives:

Targeting Rb mutant cancers by inactivating TSC2

Jennifer S. Searle, Binghui Li and Wei Du _

PDF | How to cite

Oncotarget. 2010; 1:228-232. https://doi.org/10.18632/oncotarget.130

Metrics: PDF 3636 views | ?

Abstract

Received: July 23, 2010, Accepted: July 25, 2010, Published: July 26, 2010

Retinoblastoma (Rb), a tumor suppressor gene, is inactivated in many types of cancer. However little is known about how the loss of Rb function can be targeted in cancer therapies. We have identified that inactivation of TSC2 in Rb mutant cancer cells will induce a synergistic cell death. The synergistic cell death is due to an increase in cellular stress including, metabolic, ER, and oxidative stress. Therefore, inactivation of TSC2 and chemothereputics that result in induction of cellular stress may be a novel and effective way to treat cancers containing inactivated Rb.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 130

Publication Alerts

Research Perspectives:

Targeting Rb mutant cancers by inactivating TSC2

Abstract